Synthesis and Optimization of Mesoporous Silica Nanoparticles for Ruthenium Polypyridyl Drug Delivery
The ruthenium polypyridyl complex [Ru(dppz)<sub>2</sub>PIP]<sup>2+</sup> (dppz: dipyridophenazine, PIP: (2-(phenyl)-imidazo[4,5-f ][1,10]phenanthroline), or Ru-PIP, is a potential anticancer drug that acts by inhibiting DNA replication. Due to the poor dissolution of Ru-PIP i...
Saved in:
Main Authors: | , , , , |
---|---|
Format: | Book |
Published: |
MDPI AG,
2021-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_9aae4162b4bf455294d2345071fa84fd | ||
042 | |a dc | ||
100 | 1 | 0 | |a Siti Norain Harun |e author |
700 | 1 | 0 | |a Haslina Ahmad |e author |
700 | 1 | 0 | |a Hong Ngee Lim |e author |
700 | 1 | 0 | |a Suet Lin Chia |e author |
700 | 1 | 0 | |a Martin R. Gill |e author |
245 | 0 | 0 | |a Synthesis and Optimization of Mesoporous Silica Nanoparticles for Ruthenium Polypyridyl Drug Delivery |
260 | |b MDPI AG, |c 2021-01-01T00:00:00Z. | ||
500 | |a 10.3390/pharmaceutics13020150 | ||
500 | |a 1999-4923 | ||
520 | |a The ruthenium polypyridyl complex [Ru(dppz)<sub>2</sub>PIP]<sup>2+</sup> (dppz: dipyridophenazine, PIP: (2-(phenyl)-imidazo[4,5-f ][1,10]phenanthroline), or Ru-PIP, is a potential anticancer drug that acts by inhibiting DNA replication. Due to the poor dissolution of Ru-PIP in aqueous media, a drug delivery agent would be a useful approach to overcome its limited bioavailability. Mesoporous silica nanoparticles (MSNs) were synthesized via a co-condensation method by using a phenanthrolinium salt with a 16 carbon length chain (Phen-C<sub>16</sub>) as the template. Optimization of the synthesis conditions by Box-Behnken design (BBD) generated MSNs with high surface area response at 833.9 m<sup>2</sup>g<sup>−1</sup>. Ru-PIP was effectively entrapped in MSNs at 18.84%. Drug release profile analysis showed that Ru-PIP is gradually released, with a cumulative release percentage of approximately 50% at 72 h. The release kinetic profile implied that Ru-PIP was released from MSN by diffusion. The in vitro cytotoxicity of Ru-PIP, both free and MSN-encapsulated, was studied in Hela, A549, and T24 cancer cell lines. While treatment of Ru-PIP alone is moderately cytotoxic, encapsulated Ru-PIP exerted significant cytotoxicity upon all the cell lines, with half maximal inhibitory concentration (IC<sub>50</sub>) values determined by MTT (([3-(4,5-dimethylthiazol-2-yl)-2,5-dephenyltetrazolium bromide]) assay at 48 h exposure substantially decreasing from >30 µM to <10 µM as a result of MSN encapsulation. The mechanistic potential of cytotoxicity on cell cycle distribution showed an increase in G1/S phase populations in all three cell lines. The findings indicate that MSN is an ideal drug delivery agent, as it is able to sustainably release Ru-PIP by diffusion in a prolonged treatment period. | ||
546 | |a EN | ||
690 | |a mesoporous silica nanoparticles | ||
690 | |a ruthenium polypyridyl | ||
690 | |a drug delivery | ||
690 | |a IC<sub>50</sub> | ||
690 | |a Pharmacy and materia medica | ||
690 | |a RS1-441 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n Pharmaceutics, Vol 13, Iss 2, p 150 (2021) | |
787 | 0 | |n https://www.mdpi.com/1999-4923/13/2/150 | |
787 | 0 | |n https://doaj.org/toc/1999-4923 | |
856 | 4 | 1 | |u https://doaj.org/article/9aae4162b4bf455294d2345071fa84fd |z Connect to this object online. |